英国卫报:走向失控的博姿药妆(14)（在线收听）

These forms of outpatient care are a good earner for Boots.

这些形式的门诊护理对博姿来说是一个很好的收入来源。

Assuming each of its pharmacies churns out 400 MURs a year, that one NHS programme is worth an annual 30m pounds to the company.

假设它的每家药店每年完成400次药物使用检查，那么一个NHS项目每年对公司来说价值3000万英镑。

Stack alongside that the new medicine service (NMS) for patients on heavy-duty drugs, worth at least 25 pounds a time,

与此同时，为服用重剂量药物的患者提供的新药服务每次至少价值25英镑，

NHS flu jabs at up to 17 pounds a pop, stop-smoking clinics, and a lot of public money is being sent to private companies to look after our health.

英国国家医疗服务体系的流感疫苗注射价格高达17英镑，戒烟诊所也提供这种疫苗，还有很多公共资金被送到私人公司来照顾我们的健康。

As far back as 2010, the NHS’s own research warned that MURs were being used to cream off public money and could be “of limited benefit and cursory in nature”.

早在2010年，英国国家医疗服务体系自己的研究就警告称，药物使用检查正被用来榨取公共资金，而且可能“效益有限，而且性质草率”。

In 2013, the Pharmaceutical Journal noted that “some pharmacists face penalties for not meeting the targets, such as no pay rise or a possible loss of a bonus”.

2013年，《药学杂志》指出，“一些药剂师会因未达到目标而受到惩罚，比如不加薪或可能失去奖金”。

Yet though it has tweaked the criteria for MURs, the cash-strapped NHS has no plans to scrap the system.

然而，尽管已经调整了药物使用检查的标准，资金短缺的NHS并没有计划废除该系统。

A few chemists even falsify MURs.

一些化学家甚至对药物使用检查进行了篡改。

Those caught go in front of the regulator, the General Pharmaceutical Council, which publishes its determinations online.

那些被抓的人会到监管机构——总制药委员会面前，后者会在网上公布其裁决结果。

Sift through them and a pattern emerges.

通过筛选，一种模式出现了。

From the hearing of a Boots pharmacist in the West Midlands, April 2012:

2012年4月，西米德兰兹郡一位博姿药剂师的听证会上说：

“He said the pressure to meet targets was relentless … Area managers ringing him on a daily basis,

他说，实现目标的压力是无情的...区域经理每天都给他打电话，

asking how many (MURs) he had done and what he was going to do about them … He was told continuously that he was letting the store down …”

当被问及他已经做了多少次药物使用检查，打算怎么做时，他不断被告知他让这家店失望了...”

A Boots pharmacist in Nottingham, August 2012: “… She had felt under enormous pressure to carry out an unrealistic number of MURs …”

诺丁汉的一位博姿药剂师，2012年8月：“...她在巨大的压力下进行了不现实数量的药物使用检查...”